Imaflex Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de Imaflex aumenten en un 2.1% al año.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Packaging	13.0%
Tasa de crecimiento de los ingresos	4.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	26 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Jun 10

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

Jun 03

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Apr 19

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Mar 30

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Mar 01

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 04

Is Imaflex (CVE:IFX) A Risky Investment?

Jan 17

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Dec 30

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Dec 15

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Nov 30

What Does Imaflex's (CVE:IFX) CEO Pay Reveal?

Nov 26

Previsiones de crecimiento de beneficios e ingresos

TSXV:IFX - Estimaciones futuras de los analistas y datos financieros pasados (CAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	104	N/A	N/A	N/A	1
12/31/2024	97	N/A	N/A	N/A	1
3/31/2024	98	1	-11	0	N/A
12/31/2023	94	1	-8	5	N/A
9/30/2023	92	2	-6	7	N/A
6/30/2023	96	5	-1	12	N/A
3/31/2023	104	8	1	17	N/A
12/31/2022	112	9	3	17	N/A
9/30/2022	115	10	3	14	N/A
6/30/2022	118	10	3	12	N/A
3/31/2022	114	8	5	9	N/A
12/31/2021	107	8	6	8	N/A
9/30/2021	104	8	6	9	N/A
6/30/2021	97	7	7	9	N/A
3/31/2021	91	5	11	13	N/A
12/31/2020	87	6	10	12	N/A
9/30/2020	83	5	10	12	N/A
6/30/2020	80	4	5	10	N/A
3/31/2020	80	4	3	9	N/A
12/31/2019	81	2	4	10	N/A
9/30/2019	85	2	2	8	N/A
6/30/2019	87	2	4	7	N/A
3/31/2019	88	2	1	3	N/A
12/31/2018	86	4	-3	1	N/A
9/30/2018	85	4	0	2	N/A
6/30/2018	85	4	-1	2	N/A
3/31/2018	87	4	1	5	N/A
12/31/2017	88	4	N/A	3	N/A
9/30/2017	86	3	N/A	2	N/A
6/30/2017	82	3	N/A	4	N/A
3/31/2017	76	2	N/A	2	N/A
12/31/2016	74	0	N/A	4	N/A
9/30/2016	72	1	N/A	2	N/A
6/30/2016	72	1	N/A	2	N/A
3/31/2016	73	1	N/A	1	N/A
12/31/2015	69	1	N/A	0	N/A
9/30/2015	68	1	N/A	2	N/A
6/30/2015	66	0	N/A	-1	N/A
3/31/2015	62	0	N/A	0	N/A
12/31/2014	61	0	N/A	-1	N/A
9/30/2014	59	0	N/A	-1	N/A
6/30/2014	59	-1	N/A	0	N/A
3/31/2014	58	0	N/A	-1	N/A
12/31/2013	56	0	N/A	2	N/A
9/30/2013	54	0	N/A	2	N/A
6/30/2013	50	0	N/A	2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de IFX es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de IFX crezcan más rápidamente que el mercado Canadian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de IFX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.1% al año) de IFX crezcan más despacio que el mercado de Canadian (6.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.1% al año) de IFX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de IFX se prevé que sea elevada dentro de 3 años.

Imaflex Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Price target increased to CA$1.95

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Price target lowered to CA$0.90

Recent updates

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Investor sentiment improves as stock rises 18%

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Is Imaflex (CVE:IFX) A Risky Investment?

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

Investor sentiment deteriorates as stock falls 18%

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Imaflex Inc. Appoints Roger Tambay as CEO

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Imaflex Inc. Announces Chief Financial Officer Changes

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CA$0.18 (vs CA$0.17 in FY 2021)

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Third quarter 2022 earnings released: EPS: CA$0.06 (vs CA$0.055 in 3Q 2021)

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Submits Advaseal® Registration Package to the EPA

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: CA$0.07 (vs CA$0.04 in 2Q 2021)

VP of Manufacturing recently sold CA$56k worth of stock

First quarter 2022 earnings released: EPS: CA$0.04 (vs CA$0.039 in 1Q 2021)

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Full year 2021 earnings released: EPS: CA$0.17 (vs CA$0.13 in FY 2020)

Imaflex Inc., Annual General Meeting, Jun 16, 2022

Imaflex Inc. Appoints Roberto Longo as Director, Chair the Audit Committee

Imaflex Inc. Announces Resignation of Mario Settino as Director

Vice-President of Corporate Affairs recently sold CA$56k worth of stock

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Imaflex (CVE:IFX) Could Easily Take On More Debt

Insider recently sold CA$520k worth of stock

VP of Manufacturing recently sold CA$98k worth of stock

Insider exercised options to buy CA$540k worth of stock.

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Vice-President of Corporate Affairs exercised options to buy CA$735k worth of stock.

Second quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.007 in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

First quarter 2021 earnings released: EPS CA$0.039 (vs CA$0.062 in 1Q 2020)

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS CA$0.13 (vs CA$0.031 in FY 2019)

Investor sentiment improved over the past week

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Imaflex Announces Positive Independent Results for the ADVASEAL Release Study

New 90-day high: CA$1.22

Is Imaflex (CVE:IFX) A Risky Investment?

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Insider recently sold CA$108k worth of stock

Revenue beats expectations

Imaflex Inc. Updates on Its ADVASEAL Study

What Does Imaflex's (CVE:IFX) CEO Pay Reveal?

New 90-day high: CA$0.78

New 90-day high: CA$0.77

Price target lowered to CA$0.90

First half earnings released

Previsiones de crecimiento de beneficios e ingresos